Erlotinib NSCLC Combo Nearly Triples PFS: Shanghai Study
This article was originally published in PharmAsia News
Executive Summary
The OPTIMAL study has confirmed that erlotinib (Roche’s Tarceva) had good efficacy and safety in non-small cell lung cancer patients with EGFR mutations.